

***Fiscal Year 2024 Department of Defense Breast Cancer Research Program (BCRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Breakthrough Award Levels 1 and 2</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524BCRPBTA122</p>	<ul style="list-style-type: none"> • Investigators at all academic levels (or equivalent) • Applications from postdoctoral fellows are encouraged under Funding Levels 1 and 2. • <i>Each investigator may be named as a Principal Investigator (PI) or Initiating PI on only one application per funding level for the Breakthrough Award Levels 1 and 2.</i> • <i>There are no limitations on the number of applications for which an investigator may be named as a Partnering PI. However, investigators are discouraged from being named as a Partnering PI on multiple FY24 Breakthrough Award Levels 1 and 2 applications unless they are clearly unique, meaningful partnerships addressing distinct research questions.</i> 	<ul style="list-style-type: none"> • Supports promising research that has high potential to lead to or make breakthroughs in breast cancer. • Research should have the potential for a major impact and accelerate progress toward ending breast cancer. • Potential impact of the research may be near-term or long-term, but it must move beyond a minor advancement and have the potential to lead to a fundamentally new approach that is significantly more effective than interventions already approved or in clinical development. • Partnering PI Option allows two PIs, termed the Initiating and Partnering PIs, to partner on a single application. <ul style="list-style-type: none"> ○ Each PI is expected to bring distinct contributions to the application. ○ The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. ○ <i>Applications where one PI is providing samples, animal models, or investigational agents while the other PI is conducting most or all of the experiments and analyses do not meet the intent of the Partnering PI Option.</i> 	<p>Funding Level 1:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$450,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. <p>Funding Level 1 with Partnering PI Option:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$750,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. <p>Funding Level 2:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1.0 million (M) for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): September 12, 2024 5:00 p.m. Eastern time</p> <p>Application: September 26, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		<p>The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level:</p> <ul style="list-style-type: none"> • Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development or is an untested theory that addresses an important problem. To foster research that yields new avenues of investigation, preliminary data are not required. Proof of concept is the anticipated outcome. • Funding Level 2: Research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within the <i>breast cancer landscape</i>. • Funding Level 2 – Population Science and Prevention Studies: Studies that investigate why certain human patient populations differ in cancer risk or clinical prognosis. The studies should focus on the analysis of human data and biospecimens and, with compelling justification, may request higher levels of funding and an additional year in the period of performance. <p><u>Funding Levels 1 and 2</u></p> <ul style="list-style-type: none"> • Submission of a Letter of Intent is required prior to full application submission. 	<p>Funding Level 2 – Population Science and Prevention Studies:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1.5M for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. <p>Funding Level 2 with Partnering PI Option:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1.5M for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. <p>Funding Level 2 – Population Science and Prevention Studies with Partnering PI Option:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2.0M for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Research Extension Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524BCRPREA2</p>	<ul style="list-style-type: none"> Independent Investigators at all academic levels (or equivalent) <i>There are no limitations on the number of applications for which an investigator may be named as a PI, Initiating PI, or Partnering PI for the Clinical Research Extension Award.</i> <i>Investigators named on an application submitted under funding opportunity HT942524BCRPREA are not eligible to submit a pre-application or full application for the same research project under the current funding opportunity.</i> <i>Investigators are discouraged from being named on multiple applications unless they are clearly addressing distinct research questions.</i> 	<ul style="list-style-type: none"> Supports research that extends or expands the data collection, follow-up, and analysis of breast cancer clinical studies. Intended to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. Although not all-inclusive, proposed research may entail a deeper molecular analysis of clinical samples, initiation of new correlative studies, biomarker validation, or continuing clinical follow-up of patients enrolled in an open/ongoing or completed clinical trial. Proposed research may be hypothesis-testing or -generating or may be designed to generate clinically annotated and molecularly characterized experimental platforms. Projects proposing to conduct clinical trials will not be supported. Partnering PI Option allows two PIs, termed the Initiating and Partnering PIs, to partner on a single application. <ul style="list-style-type: none"> Each PI is expected to bring a distinct contribution to the application. The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. <p><u>Additional Elements</u></p> <ul style="list-style-type: none"> Submission of a Letter of Intent is required prior to full application submission. Applications must include two or more breast cancer advocates on the research team. 	<p>Clinical Research Extension Award:</p> <ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$5.0M for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 4 years. <p>Clinical Research Extension Award with Partnering PI Option:</p> <ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$6.0M for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): September 12, 2024 5:00 p.m. Eastern time</p> <p>Application: September 26, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Era of Hope Scholar Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524BCRPEOHS2</p>	<ul style="list-style-type: none"> Independent, non-mentored investigators within 6 years of their last training position as of the application submission deadline (excluding time spent on family medical leave) Postdoctoral fellows, clinical fellows (including residents and interns), and other researchers currently in training positions are not eligible. <i>Investigators named as a PI on an application submitted under funding opportunity HT942524BCRPEOHS are not eligible as a PI under the current funding opportunity.</i> 	<ul style="list-style-type: none"> Supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer. Individuals should be exceptionally talented scientists who have shown that they are the “best and brightest” in their field(s) through extraordinary creativity, vision, innovation and productivity. PIs should have demonstrated experience in forming effective partnerships and collaborations and must exhibit strong potential for future leadership in breast cancer research. Applications should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention. <i>Experience in breast cancer research is not required</i>; however, the application must focus on breast cancer, and the PI must commit a minimum of 25% level of time and effort during the period of performance to conduct breast cancer research under this award. <p><u>Additional Elements</u></p> <ul style="list-style-type: none"> Submission of a Letter of Intent is required prior to full application submission. Applications must include two or more breast cancer advocates on the research team. 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$3.5M for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): July 23, 2024 5:00 p.m. Eastern time</p> <p>Application: August 6, 2024 11:59 p.m. Eastern time</p> <p>Confidential Letters of Recommendation Submission Deadline: August 9, 2024 5:00 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Transformative Breast Cancer Consortium Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524BCRPTBCCDA2</p>	<ul style="list-style-type: none"> Independent investigators at all academic levels (or equivalent) <i>Investigators named as Consortium Director on a pre-application or full application submitted under funding opportunity HT942524BCRPTBCCA are not eligible.</i> <i>Investigators named as PI on an application submitted under funding opportunity HT942524BCRPTBCCDA are not eligible to submit a pre-application or full application for the same consortium under the current funding opportunity.</i> 	<ul style="list-style-type: none"> Provides the time and resources needed to bring investigators and breast cancer advocates together to establish a consortium framework and conduct preliminary research to support application to a future, full Transformative Breast Cancer Consortium Award (pending availability of funds). Supports the following: (1) development of the infrastructure of a multi-institutional research team inclusive of scientists, clinicians, and breast cancer advocates; (2) generation of necessary preliminary data to serve as proof of concept or for project integration; (3) acquisition of research resources; and (4) development of a framework of necessary statistical analyses. <p><u>Additional Elements</u></p> <ul style="list-style-type: none"> Submission of a Letter of Intent is required prior to full application submission. PIs are required to include breast cancer advocate(s) on the research team. 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$100,000 for direct costs. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. The maximum period of performance is 1 year. 	<p>Pre-Application (Letter of Intent): September 12, 2024 5:00 p.m. Eastern time</p> <p>Application: September 26, 2024 11:59 p.m. Eastern time</p>